Recent successes in virtual screening have been made possible by large models and extensive chemical libraries. However, combining these elements is challenging: the larger the model, the more expensive it is to run, making ultra-large libraries unfeasible. To address this, we developed a target-agnostic, efficacy-based molecule search model, which allows us to find structurally dissimilar molecules with similar biological activities. We used the best practices to design fast retrieval system, based on processor-optimized SIMD instructions, enabling us to screen the ultra-large 40B Enamine REAL library with 100\% recall rate. We extensively benchmarked our model and several state-of-the-art models for both speed performance and retrieval quality of novel molecules.
Read the paper
Read the paper
Related
Publications
BIOPTIC B1 Identifies Novel Miro1 ligands for Friedreich's ataxia — Stanford-led Cell Chemical Biology Study
Read more
BIOPTIC B1 Identifies Novel Miro1 ligands for Friedreich's ataxia — Stanford-led Cell Chemical Biology Study
Publications
BIOPTIC Agent Hunt Globally — Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence (arXiv, 2026)
Read more
BIOPTIC Agent Hunt Globally — Wide Search AI Agents for Drug Asset Scouting in Investing, Business Development, and Competitive Intelligence (arXiv, 2026)
Publications
BIOPTIC B1 Ultra-High-Throughput Virtual Screening System Discovers LRRK2 Ligands in Vast Chemical Space
Read more
BIOPTIC B1 Ultra-High-Throughput Virtual Screening System Discovers LRRK2 Ligands in Vast Chemical Space
Thanks for getting in touch.
We’ve received your inquiry and will follow up by email.
Your form wasn’t submitted. Please try again or email office@bioptic.io.